U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including, http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdf

Bleomycin sulfate is an antineoplastic antibiotic isolated from Streptomyces verticillus. It is a mixture of glycopeptide antibiotics containing primarily Bleomycin A2 (~70%) and B2 (~30%). Bleomycin binds to DNA, inhibits DNA synthesis, and causes single strand scission of DNA in vivo and in vitro at specific base sequences.

CNS Activity

Curator's Comment: Bleomycin does not cross the blood-brain barrier.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1973
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1973
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1973
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1973
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1973
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1975
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1975
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1975
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1975
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1975
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1975
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1975
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1975
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1975
PubMed

PubMed

TitleDatePubMed
Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin.
1985 Dec 15
Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer.
1990 Feb 24
Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin.
1990 Jul
Hemolytic-uremic syndrome associated with neoadjuvant chemotherapy in the treatment of advanced cervical cancer.
1990 Nov
Selective loss of optic nerve beta-tubulin in vincristine-induced blindness.
1992 Aug
Overexpression of wild-type and nuclear-targeted catalase modulates resistance to oxidative stress but does not alter spontaneous mutant frequencies at APRT.
2000 Apr 3
Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12.
2001 Jun
Serum SP-D is a marker of lung injury in rats.
2002 Apr
A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
2002 Aug
Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.
2003 Mar
The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
2004 Dec
Use of toxicogenomics for identifying genetic markers of pulmonary oedema.
2005 Apr 15
[Rat alveolar type II injured by bleomycin].
2005 Feb
Effect of Feitai on bleomycin-induced pulmonary fibrosis in rats.
2005 Jan 15
Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice.
2007 Dec
Early lung injury contributes to lung fibrosis via AT1 receptor in rats.
2007 Feb
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
2007 Feb 10
BMP-7 does not protect against bleomycin-induced lung or skin fibrosis.
2008
Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.
2009 Feb
Bleomycin-induced nuclear factor-kappaB activation in human bronchial epithelial cells involves the phosphorylation of glycogen synthase kinase 3beta.
2009 Jun 22
Essential role of MeCP2 in the regulation of myofibroblast differentiation during pulmonary fibrosis.
2011 Apr
Anti-inflammatory and antifibrotic effects of methyl palmitate.
2011 Aug 1
Links between DNA polymerase beta expression and sensitivity to bleomycin.
2011 Mar 15
Testing chemical agents with the cytokinesis-block micronucleus cytome assay.
2012
Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice.
2012 Aug 15
Thymoquinone blocks lung injury and fibrosis by attenuating bleomycin-induced oxidative stress and activation of nuclear factor Kappa-B in rats.
2012 Dec 16
The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals.
2012 Jan
Suppression of nuclear factor erythroid 2-related factor 2 via extracellular signal-regulated kinase contributes to bleomycin-induced oxidative stress and fibrogenesis.
2013 Jun 20
Direct activation of ATM by resveratrol under oxidizing conditions.
2014
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Bleomycin can be given intramuscularly, or subcutaneously in Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma, Hodgkin’s disease and as a single dose bolus intrapleural injection (60 units) in Malignant Pleural Effusion.
0.25 to 0.50 units/kg weekly or twice weekly (Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma, Hodgkin’s disease)
Route of Administration: Intravenous
1-200 ug/ml
Substance Class Mixture
Created
by admin
on Fri Dec 15 16:28:28 GMT 2023
Edited
by admin
on Fri Dec 15 16:28:28 GMT 2023
Record UNII
40S1VHN69B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BLEOMYCIN
HSDB   INN   VANDF   WHO-DD  
INN  
Official Name English
Bleomycin [WHO-DD]
Common Name English
BLEOMYCIN HYDROCHLORIDE [JAN]
Common Name English
BLEOMYCIN [VANDF]
Common Name English
BLENAMAX
Brand Name English
NSC-125066
Code English
BLEOMYCINS
MI  
Common Name English
bleomycin [INN]
Common Name English
BLEOMYCINS [MI]
Common Name English
BLEOMYCIN [IARC]
Common Name English
BLEOMYCIN [HSDB]
Common Name English
BLEOMYCIN HEXAL
Brand Name English
BLEO
Brand Name English
BLEOCIN
Brand Name English
BLEOMYCINS [IARC]
Common Name English
MIXTURE OF CYTOTOXIC GLYCOPEPTIDES PRODUCED BY THE GROWTH OF STREPTOMYCES VERTICILLUS
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548499
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
WHO-VATC QL01DC01
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
NCI_THESAURUS C2311
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
NDF-RT N0000180854
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
FDA ORPHAN DRUG 118498
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
FDA ORPHAN DRUG 326510
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
WHO-ATC L01DC01
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
Code System Code Type Description
DRUG CENTRAL
4742
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
CHEBI
3139
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
LACTMED
Bleomycin
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
RXCUI
1622
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY RxNorm
EVMPD
SUB00842MIG
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
HSDB
3208
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
ChEMBL
CHEMBL3039590
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
NSC
125066
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
MESH
D001761
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
EPA CompTox
DTXSID1030862
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
CAS
11056-06-7
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
NCI_THESAURUS
C313
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
FDA UNII
40S1VHN69B
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
MERCK INDEX
m2589
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY Merck Index
DRUG BANK
DB00290
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
WIKIPEDIA
BLEOMYCIN
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
INN
2721
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
DAILYMED
40S1VHN69B
Created by admin on Fri Dec 15 16:28:28 GMT 2023 , Edited by admin on Fri Dec 15 16:28:28 GMT 2023
PRIMARY
All of the following components must be present:
Related Record Type Details
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Definition References